Iterum Therapeutics Reveals Essential Data at IDWeek 2024
Iterum Therapeutics plc (Nasdaq: ITRM), a leading pharmaceutical company from Dublin and Chicago, is dedicated to developing advanced antibiotics to tackle the growing issue of multi-drug resistant pathogens. They recently announced that they will present innovative data at the IDWeek 2024 conference, a significant event for the field of infectious diseases.
What Will Be Presented
During this prestigious conference, which takes place in Los Angeles, the company will showcase three pivotal posters that highlight their latest research and findings.
Study on Oral Sulopenem/probenecid
One of the key presentations is titled "Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial." This study, presented by Steven I. Aronin, MD, will delve into new insights regarding a promising treatment option for urinary tract infections. It is scheduled for October 18, from 12:15 p.m. to 1:30 p.m., which reflects the commitment of Iterum Therapeutics to address common yet serious infections.
Analysis of Asymptomatic Bacteriuria
Another important piece of research being presented is "Asymptomatic Bacteriuria Not a Predictor of Clinical Failure in Uncomplicated Urinary Tract Infections (uUTI): A Prospective Analysis of Women Treated for uUTI from the REASSURE Trial." Dr. Aronin will also lead this presentation, showcasing an in-depth analysis that will provide valuable information on treatment outcomes, scheduled for a rapid fire format on October 18.
Sulopenem's Efficacy in Inhalational Anthrax
The final featured presentation is titled "Sulopenem is Efficacious in a Rabbit Model of Inhalational Anthrax." This study will highlight Sulopenem's effectiveness in an area of great concern, marking a significant addition to the knowledge base in treating severe bacterial infections.
Access to Poster Information
All of the information regarding these presentations will be made publicly available on the company’s website. After the conclusion of the conference, interested parties can visit the "Posters & Presentations" section under the “Our Science” tab to access the posters and learn more about the findings.
About Iterum Therapeutics plc
Iterum Therapeutics plc is on the forefront of combatting the critical challenge posed by multi-drug resistant pathogens. With their primary focus on developing anti-infective therapies, Iterum is advancing its main compound, sulopenem, which exists in both oral and IV formulations. This novel penem anti-infective has shown remarkable effectiveness against various gram-negative and gram-positive bacteria, showcasing powerful activity even against strains resistant to other treatments.
The company has actively submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the oral formulation of sulopenem targeted at uncomplicated urinary tract infections, marking a significant step forward in providing viable treatment options. Moreover, sulopenem has received esteemed designations such as Qualified Infectious Disease Product (QIDP) and Fast Track status in several indications.
Investor Relations
For inquiries, Judy Matthews, Chief Financial Officer, can be reached at 312-778-6073 or via email.
Frequently Asked Questions
1. What is the primary focus of Iterum Therapeutics?
Iterum Therapeutics focuses on developing next-generation antibiotics to tackle multi-drug resistant infections.
2. When is IDWeek 2024 scheduled?
IDWeek 2024 is scheduled for October 16-19.
3. Who is presenting the research at the conference?
Dr. Steven I. Aronin is presenting the key research findings at IDWeek 2024.
4. What is Sulopenem?
Sulopenem is Iterum's leading anti-infective compound that targets various bacterial infections.
5. How can I find the posters presented at the conference?
The posters will be accessible on Iterum Therapeutics' website post-conference under the “Our Science” section.
